James Larkin, MD, PhD, of the Royal Marsden NHS Foundation Trust, London, UK, explains the treatment options available for patients with stage III melanoma, which means that the disease has been cured with surgery but there is a risk of it coming back. According to Dr Larkin, treatment options are limited and usually participation in clinical trials is the recommended option for such patients. Last year, there was a trial comparing nivolumab and ipilimumab (IPI), and now there is a trial involving the use of pembrolizumab (PEMBRO) as a treatment option. For patients with stage III melanoma that cannot be removed using surgical means, there are several different treatment options (the use of drugs, for instance), but each patient is usually considered on an individualized basis. Recorded at the American Society of Oncology (ASCO) 2016 Annual Meeting held in Chicago, IL.

свернуть